Analyzing body fluids in narcolepsy patients
Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
This study looks at body fluids from people with narcolepsy and healthy volunteers to see if there are any unique markers that could help better understand the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 5 Years to 100 Years |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06279247 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the proteomics and metabolomics of body fluids in patients with narcolepsy, comparing them to healthy volunteers. It aims to identify potential molecular markers associated with narcolepsy by analyzing blood, urine, stool, and cerebrospinal fluid samples. The study will assess various factors, including sleepiness and sleep quality, using established scales. By understanding the biochemical differences, the research seeks to shed light on the pathogenesis of narcolepsy and improve diagnostic accuracy.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with narcolepsy type 1 or type 2 according to the International Classification of Sleep Disorders.
Not a fit: Patients with primary hypersomnia, other sleep disorders, or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic tools and treatment strategies for narcolepsy patients.
How similar studies have performed: While the approach of using proteomics and metabolomics in narcolepsy is relatively novel, similar methodologies have shown promise in other neurological conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3). Exclusion Criteria * primary hypersomnia or hypersomnia due to shift work, sleep deprivation and other sleep rhythm disturbances; * excessive sleep due to drug abuse; * suffering from Parkinson's disease, Alzheimer's disease and other nervous system diseases and mental diseases; * complicated with heart, lung, liver, kidney, blood endocrine system and other basic diseases, or acute chronic infection in a short period of time; * Use of sedatives, hypnotics, antidepressants, lithium and dopamine receptor antagonists for two weeks before examination; * patients who cannot cooperate with PSG and MSLT due to various factors.
Where this trial is running
Jinan, Shandong
- Qilu Hospital of Shandong University — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: haiyun li
- Email: haiyunli1122@163.com
- Phone: 18560088921
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.